Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Expands By 75.3%

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 128,000 shares, an increase of 75.3% from the January 31st total of 73,000 shares. Based on an average trading volume of 41,000 shares, the days-to-cover ratio is presently 3.1 days. Approximately 1.2% of the shares of the company are short sold.

Analyst Ratings Changes

A number of research firms recently issued reports on TLSI. Roth Mkm restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective for the company. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Finally, Lake Street Capital started coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, TriSalus Life Sciences presently has a consensus rating of “Buy” and a consensus target price of $11.56.

TriSalus Life Sciences Trading Down 1.9 %

Shares of TLSI opened at $5.65 on Tuesday. The firm has a market cap of $172.29 million, a P/E ratio of -2.27 and a beta of 0.51. The stock’s 50 day moving average is $5.22 and its two-hundred day moving average is $4.72. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42.

Insiders Place Their Bets

In other news, major shareholder Equity Ab Frankenius bought 62,972 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average price of $3.97 per share, with a total value of $249,998.84. Following the completion of the acquisition, the insider now directly owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. This trade represents a 1.02 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James Emmett Young bought 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was purchased at an average price of $5.65 per share, for a total transaction of $33,900.00. Following the transaction, the chief financial officer now owns 30,000 shares of the company’s stock, valued at $169,500. The trade was a 25.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 117,828 shares of company stock valued at $544,607. 32.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Walleye Capital LLC acquired a new position in TriSalus Life Sciences during the third quarter worth $66,000. MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences during the third quarter worth about $184,000. Vestcor Inc acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth about $108,000. Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter worth about $92,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.